<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[clinical trial Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/clinical+trial.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to clinical trial]]></description>
	<s:counts start="0" returned="20" found="546" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Human Genome, Glaxo Lupus Drug Works in 2nd Trial]]></title>
		<link><![CDATA[http://www.bnet.com/2407-14055_23-359420.html]]></link>
		<description><![CDATA[By Toni Clarke and Ben HirschlerBOSTON/LONDON (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>) - Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 years.Shares in Human Genome jumped 40 percent in pre-market...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Mon, 02 Nov 2009 07:00:28 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/genome.html"><![CDATA[Genome]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/benlysta.html"><![CDATA[Benlysta]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/human.html"><![CDATA[Human]]></category>
		<category domain="http://resources.bnet.com/topic/lupus+research+institute.html"><![CDATA[Lupus Research Institute]]></category>
		<category domain="http://resources.bnet.com/topic/us.html"><![CDATA[Us]]></category>
	</item>
	<item>
		<title><![CDATA[PhRMA's New Clinical Trial Guidelines Leave Plenty of Room for Maneuver]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004556/phrmas-new-clinical-trial-guidelines-leave-plenty-of-room-for-maneuver/]]></link>
		<description><![CDATA[Two cheers for PhRMA, which has produced a set of guidelines urging its members to conduct clinical trials in a more fair manner -- and to stop bribing doctors with fancy trips to the Caribbean. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 01 Oct 2009 08:38:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/guideline.html"><![CDATA[Guideline]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/phrma.html"><![CDATA[PhRMA]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Abbott Developing Painkiller Spray for Dogs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003833/abbott-developing-painkiller-spray-for-dogs/]]></link>
		<description><![CDATA[Abbott Labs is developing a painkiller spray for pet dogs, the company said. In a partnership with Velcera, Abbott is in clinical trials to bring Promist to market. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 21 Aug 2009 07:27:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/spray.html"><![CDATA[Spray]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+labs.html"><![CDATA[Abbott Labs]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[MEDTOX Scientific, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-320735.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions Your first question comes from Steven Crowley &#8211; Craig-Hallum Capital.   Steven Crowley &#8211; Craig Hallum Capital I think last quarter you were able to share with us some statistics or metrics on either the number of customers versus a year ago, or...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 15 Jul 2009 09:38:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/medtox+scientific+inc..html"><![CDATA[Medtox Scientific Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MTOX</category>
		<category domain="tickers">MTOX</category>
	</item>
	<item>
		<title><![CDATA[Myelin Repair Foundation: Can You Fund A Clinical Trial $5 At A Time?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002699/myelin-repair-foundation-can-you-fund-a-clinical-trial-5-at-a-time/]]></link>
		<description><![CDATA[The Myelin Repair Foundation has made a name for itself by applying biotech-style business savvy to the world of nonprofit research. Unfortunately, the charity has also run into some biotech-style problems, specifically, difficulty finding a partner or funding to back its clinical trials. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 16 Jun 2009 11:14:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/myelin+repair+foundation.html"><![CDATA[Myelin Repair Foundation]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
	<item>
		<title><![CDATA[Palatin Technologies, Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-274171.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions Your first question comes from the line of Amy Wang - MDB Capital Group, LLC. Amy Wang - MDB Capital Group LLC My first question, can you remind us, I know you talked about your continued partnership discussions for your clinical and preclinical program....]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 02 Mar 2009 06:03:19 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/program.html"><![CDATA[Program]]></category>
		<category domain="http://resources.bnet.com/topic/partnership.html"><![CDATA[Partnership]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/palatin+technologies+inc..html"><![CDATA[Palatin Technologies Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PTN</category>
		<category domain="tickers">PTN</category>
	</item>
	<item>
		<title><![CDATA[NEJM: Foreign Drug Trials Could Hurt U.S. Patients]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001071/nejm-foreign-drug-trials-could-hurt-us-patients/]]></link>
		<description><![CDATA[The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 19 Feb 2009 07:56:45 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/argentine+authority.html"><![CDATA[Argentine Authority]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[How To Value A Biotechnology Company]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=953551]]></link>
		<description><![CDATA[The major risk to be quantified in the valuation of a biotechnology company is the risk of successfully completing clinical trials. In order to accurately asses the value of a biotech company, it is crucial to have an understanding of the clinical development process for human therapeutics - the costs,...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 01 Jan 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/risk.html"><![CDATA[Risk]]></category>
		<category domain="http://resources.bnet.com/topic/deloitte+llp.html"><![CDATA[Deloitte LLP]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
	</item>
	<item>
		<title><![CDATA[China Medical Technologies F2Q08 (Qtr End 9/30/08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-256358.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions And our first question will come from the line of Ben Lee with Morgan Stanley. Ben Lee - Morgan Stanley Thanks for taking my call. I have a few questions. First, can you tell us how profitable was the HIFU business historically and what&#8217;s...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 18 Dec 2008 08:19:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/operating+profit.html"><![CDATA[Operating Profit]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/business.html"><![CDATA[Business]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/hifu.html"><![CDATA[HIFU]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
	</item>
	<item>
		<title><![CDATA[BioSante: Key Support Is Back]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F106100-biosante-key-support-is-back%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Earlier this week BioSante Pharma BPAX reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 14 Nov 2008 11:57:43 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/biosante+pharmaceutical+inc..html"><![CDATA[Biosante Pharmaceutical Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BPAX</category>
		<category domain="tickers">BPAX</category>
	</item>
	<item>
		<title><![CDATA[Cytori Therapeutics, Third Quarter Year Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-248081.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator   Thank you sir, at this time we will begin the Question-and-answer session.  Operator Instructions.   Our first question comes from the line of Steve Brozak with WBB Securities.  Please go ahead. Stephen Brozak - Westerfield, Bakerink, Brozak   Well congratulations...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 10 Nov 2008 12:08:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/cytori+therapeutics+inc..html"><![CDATA[Cytori Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTX</category>
		<category domain="tickers">CYTX</category>
	</item>
	<item>
		<title><![CDATA[Cross Country Healthcare Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14031_23-246123.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Jim Janesky &#8211; Stifel Nicolaus & Company, Inc. James Janesky &#8211; Stifel Nicolaus & Company, Inc. When you look at the fourth quarter can you give us an idea by segment the direction of weakness?  I would imagine that...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 03 Nov 2008 14:56:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/segment.html"><![CDATA[Segment]]></category>
		<category domain="http://resources.bnet.com/topic/physician.html"><![CDATA[Physician]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/cross+country+healthcare+inc..html"><![CDATA[Cross Country Healthcare Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/physician+staffing.html"><![CDATA[Physician Staffing]]></category>
		<category domain="http://resources.bnet.com/topic/contribution+margin.html"><![CDATA[Contribution Margin]]></category>
		<category domain="http://resources.bnet.com/topic/human+capital.html"><![CDATA[Human Capital]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/segment.html"><![CDATA[Segment]]></category>
		<category domain="http://resources.bnet.com/topic/physician.html"><![CDATA[Physician]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/cross+country+healthcare+inc..html"><![CDATA[Cross Country Healthcare Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/physician+staffing.html"><![CDATA[Physician Staffing]]></category>
		<category domain="http://resources.bnet.com/topic/contribution+margin.html"><![CDATA[Contribution Margin]]></category>
		<category domain="http://resources.bnet.com/topic/human+capital.html"><![CDATA[Human Capital]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CCRN</category>
		<category domain="tickers">CCRN</category>
	</item>
	<item>
		<title><![CDATA[MEDTOX Scientific, Inc.  Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-242053.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Steven Crowley &#8211; Craig-Hallum Capital.     Steven Crowley &#8211; Craig Hallum Capital A couple of questions for you, obviously the clinical trials related laboratory services business had a great quarter.  I'm wondering how sustainable the level...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 16 Oct 2008 15:04:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/quarter.html"><![CDATA[Quarter]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/medtox+scientific+inc..html"><![CDATA[Medtox Scientific Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/quarter.html"><![CDATA[Quarter]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/medtox+scientific+inc..html"><![CDATA[Medtox Scientific Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MTOX</category>
		<category domain="tickers">MTOX</category>
	</item>
	<item>
		<title><![CDATA[Amarin Corporation plc Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-237017.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instruction Your first question comes from Stephen Handley -h JM Dutton Associates. Stephen Handley &#8211; JM Dutton Associates Let me ask you whether with the new management and new investors now on the Board as well, have there been any important shifts in these development priorities?...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Sep 2008 07:47:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[Financial]]></category>
		<category domain="http://resources.bnet.com/topic/cash+flow.html"><![CDATA[Cash Flow]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/lovaza.html"><![CDATA[Lovaza]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
	</item>
	<item>
		<title><![CDATA[Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_10/ai_n25492539]]></link>
		<description><![CDATA[WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics TM, today announced the initiation of a Phase 2 clinical trial of AZD3480 (TC-1734) in adults with Attention Deficit/Hyperactivity Disorder, or ADHD.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 10 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[Cytokinetics Announces Clinical Trials Data Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25479707]]></link>
		<description><![CDATA[Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its oncology programs were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology ASCO in Chicago, IL. Two of these abstracts related to clinical trials evaluating ispinesib, one trial sponsored...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/abstract.html"><![CDATA[abstract]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_22/ai_n25450354]]></link>
		<description><![CDATA[COLLEGEVILLE, Pa. & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR([TM]) methylnaltrexone bromide.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 22 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Phase Forward: Boooooring]]></title>
		<link><![CDATA[http://www.bnet.com/2422-17910_23-201606.html]]></link>
		<description><![CDATA[Phase Forward monitors clinical trials around the world and spurred the move to web-based trials ten years ago. But their boring technology helps us all not die from the latest meds. Which is sort of exciting.]]></description>
		<s:doctype><![CDATA[Videos]]></s:doctype>
		<pubDate>Wed, 02 Apr 2008 04:34:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/phase+forward+incorporated.html"><![CDATA[Phase Forward Incorporated]]></category>
		<category domain="http://resources.bnet.com/topic/pfwd.html"><![CDATA[PFWD]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trails.html"><![CDATA[clinical trails]]></category>
		<category domain="http://resources.bnet.com/topic/web+based.html"><![CDATA[web based]]></category>
		<category domain="http://resources.bnet.com/topic/research.html"><![CDATA[research]]></category>
		<category domain="http://resources.bnet.com/topic/back+to+the+future.html"><![CDATA[back to the future]]></category>
		<category domain="http://resources.bnet.com/topic/rocky.html"><![CDATA[rocky]]></category>
		<category domain="http://resources.bnet.com/topic/david+hasselhoff.html"><![CDATA[david hasselhoff]]></category>
		<category domain="http://resources.bnet.com/topic/web+video.html"><![CDATA[web video]]></category>
		<category domain="http://resources.bnet.com/topic/cbs.html"><![CDATA[cbs]]></category>
		<category domain="http://resources.bnet.com/topic/cbs+news.html"><![CDATA[cbs news]]></category>
		<category domain="http://resources.bnet.com/topic/cbs.com.html"><![CDATA[cbs.com]]></category>
		<category domain="http://resources.bnet.com/topic/howard+lindzon.html"><![CDATA[howard lindzon]]></category>
		<category domain="http://resources.bnet.com/topic/closing+bell.html"><![CDATA[closing bell]]></category>
		<category domain="http://resources.bnet.com/topic/julie+alexandria.html"><![CDATA[julie alexandria]]></category>
		<category domain="http://resources.bnet.com/topic/wallstrip.html"><![CDATA[wallstrip]]></category>
		<category domain="http://resources.bnet.com/topic/wallstreet.html"><![CDATA[wallstreet]]></category>
		<category domain="http://resources.bnet.com/topic/stocks.html"><![CDATA[stocks]]></category>
		<category domain="http://resources.bnet.com/topic/stock+market.html"><![CDATA[stock market]]></category>
		<category domain="http://resources.bnet.com/topic/stock+exchange.html"><![CDATA[stock exchange]]></category>
		<category domain="http://resources.bnet.com/topic/money.html"><![CDATA[money]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[finance]]></category>
		<category domain="http://resources.bnet.com/topic/investing.html"><![CDATA[investing]]></category>
		<category domain="http://resources.bnet.com/topic/invest.html"><![CDATA[invest]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq.html"><![CDATA[nasdaq]]></category>
		<category domain="http://resources.bnet.com/topic/nyse.html"><![CDATA[nyse]]></category>
		<category domain="http://resources.bnet.com/topic/cash.html"><![CDATA[cash]]></category>
		<category domain="http://resources.bnet.com/topic/business.html"><![CDATA[business]]></category>
		<category domain="http://resources.bnet.com/topic/warren.html"><![CDATA[warren]]></category>
		<category domain="http://resources.bnet.com/topic/buffet.html"><![CDATA[buffet]]></category>
		<category domain="http://resources.bnet.com/topic/berkshire+hathaway.html"><![CDATA[berkshire hathaway]]></category>
		<category domain="http://resources.bnet.com/topic/day+trade.html"><![CDATA[day trade]]></category>
		<category domain="http://resources.bnet.com/topic/trends.html"><![CDATA[trends]]></category>
		<category domain="http://resources.bnet.com/topic/cnbc.html"><![CDATA[cnbc]]></category>
		<category domain="http://resources.bnet.com/topic/trading.html"><![CDATA[trading]]></category>
		<category domain="http://resources.bnet.com/topic/market.html"><![CDATA[market]]></category>
		<category domain="http://resources.bnet.com/topic/jim+cramer.html"><![CDATA[jim cramer]]></category>
		<category domain="http://resources.bnet.com/topic/britney.html"><![CDATA[britney]]></category>
	</item>
	<item>
		<title><![CDATA[Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_25/ai_n24946244]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- Elixir Pharmaceuticals, Inc., announced today that it has completed enrollment in its final pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes. The study is expected to be completed during the third quarter of 2008, with data available shortly thereafter....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 25 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_7/ai_n24378907]]></link>
		<description><![CDATA[WASHINGTON -- Alcon, Inc. (NYSE: ACL) released today the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These initial data were presented...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 07 Mar 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[clinical trial]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
